Pharvaris BV Cash Flow Conversion Efficiency
Pharvaris BV cash flow conversion efficiency. Based on the latest financial reports, Pharvaris BV (PHVS) has a cash flow conversion efficiency ratio of -0.126x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.80 Million) by net assets ($300.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pharvaris BV (2018–2025)
Cash flow conversion efficiency of Pharvaris BV from 2018 to 2025. This chart illustrates how Pharvaris BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PHVS stock price for real-time trading data and today's change.
Pharvaris BV Cash Flow Conversion Ratio Explained
Pharvaris BV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pharvaris BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharvaris BV ranked by their cash flow conversion efficiency. Also see Pharvaris BV (PHVS) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
State Grid Information&Communication Co Ltd
SHG:600131
|
0.034x |
|
Shanghai Bright Power Semiconductor
SHG:688368
|
0.016x |
|
OneStream, Inc. Class A Common Stock
NASDAQ:OS
|
0.009x |
|
Santos Brasil Participações S.A
SA:STBP3
|
0.495x |
|
Bure Equity AB
ST:BURE
|
0.016x |
|
Kalpataru Projects International Ltd.
NSE:KPIL
|
-0.053x |
|
Zhejiang Provincial New Energy Investment Group Co Ltd
SHG:600032
|
0.139x |
|
Fastly, Inc. Class A Common Stock
NYSE:FSLY
|
0.024x |
Annual Cash Flow Conversion Efficiency for Pharvaris BV (2018–2025)
The table below shows the annual cash flow conversion efficiency of Pharvaris BV from 2018 to 2025. Review Pharvaris BV financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $271.27 Million | $-137.07 Million | -0.505x | -12.63% |
| 2024-12-31 | $267.76 Million | $-120.13 Million | -0.449x | -85.17% |
| 2023-12-31 | $384.05 Million | $-93.05 Million | -0.242x | +46.16% |
| 2022-12-31 | $149.26 Million | $-67.16 Million | -0.450x | -106.78% |
| 2021-12-31 | $204.95 Million | $-44.60 Million | -0.218x | +3.05% |
| 2020-12-31 | $95.79 Million | $-21.50 Million | -0.224x | +37.23% |
| 2019-12-31 | $18.67 Million | $-6.68 Million | -0.358x | +54.81% |
| 2018-12-31 | $4.95 Million | $-3.92 Million | -0.791x | -- |
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more